by Lisa Rezende, PhD
November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher for individuals with the BRCA2 mutation than with the BRCA1 mutation. People with mutations in PALB2, STK11, CDKN2a, and other genes are also at increased risk of pancreatic cancer.
This November, learn more about hereditary pancreatic cancer by:
- Checking out our Pancreatic Cancer page for more information on other risk factors and mutations associated with pancreatic cancer
- Learning about an open clinical trial looking at the use of a targeted therapy called a PARP inhibitor in Updates on Pancreatic Cancer Genetic Research Study by Talia Golan, MD and Sue Friedman, DVM
- Reading accounts of two personal journeys with pancreatic cancer in past Voices of FORCE, Pancreatic Cancer Screening by Susan Beausang and Participating in Pancreatic Cancer Clinical Trial by David Dessert
- Watching the September 2016 Insights on Hereditary Pancreatic Cancer webinar with Dr. Michael J. Hall, MD, Director of Gastrointestinal Risk Assessment at Fox Chase Cancer Center
The FORCE community includes people affected by hereditary breast, ovarian, and related cancers—including pancreatic cancer—and we are continually adding resources on this important topic.
If you have pancreatic cancer or a close relative who has been diagnosed with pancreatic cancer and are concerned that the cancer in your family may be hereditary, see our “Should I get genetic testing?” page for information on signs of hereditary cancer.
Tags: brca, BRCA 1, BRCA 2, brca research, brca testing, BRCA2, CDKN2, PALB2, pancreatic cancer, PARP inhibitor, STK11